Breaking News, Collaborations & Alliances

Advanz Pharma & Alvotech Gain European Approval for Mynzepli

Approval is based on comprehensive analytical, non-clinical, and clinical similarity data.

By: Rachel Klemovitch

Assistant Editor

Alvotech, a global biotech company, and Advanz Pharma Holdco Limited (Advanz Pharma), a UK-headquartered global pharmaceutical company, announced that the European Commission has approved Mynzepli as a biosimilar to Eylea (aflibercept), in a pre-filled syringe and vial. Mynzepli is approved for all adult indications approved for the reference biologic, neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to macular oedema secondary to retinal vein occlusion (bran...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters